Drugs / Isoflavone
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT00925639 | Aug 2009 → Jan 2010 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 3 | NCT00905723 | May 2009 → May 2010 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00245518 | Jun 2005 → Sep 2008 | — | Johns Hopkins University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01695616 Comparator | Aug 2013 → Aug 2014 | — | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoflavone | “The purpose of this study is to evaluate the effects of Passiflora incarnata and Isoflavone combination in relieving the symptoms associated with Climacteric Syndrome.” NCT01695616 ↗ |
| Known as | NSC-135405 | ChEMBL registry synonym — accepted as the source's own label CHEMBL366460 ↗ |
| Modality | Small molecule | — CHEMBL366460 ↗ |
| Route | Oral | “Patients will receive daily doses of 150 mg of concentrated extract of soy per os” NCT00925639 ↗ |